# Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

> **NCT02893930** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Tumor G1
- Pancreatic Neuroendocrine Tumor G2
- Refractory Pancreatic Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Sapanisertib

## Key facts

- **NCT ID:** NCT02893930
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-28
- **Primary completion:** 2021-05-11
- **Final completion:** 2022-12-21
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02893930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02893930, "Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02893930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*